Loading...

EQ EQUILLIUM INC Expansion Plans 8-K Filing

QLLM

Q

EQUILLIUM INC

(EQ)

2024 8-K

Show Summary

Show Summary

Noncompliance Notice

Equity Incentive Plan amend...

Financial Statements

Financial Results

Clinical Trial Results

Nasdaq Noncompliance

Q3 Financial Results

Itolizumab Update

Nasdaq Compliance

Financial Condition

Phase 2 Study Results

Annual Meeting of Stockholders

Financial Results Announcement

Positive Data from Phase 1b...

Financial Results Announcement

Appointment of Principal Ac...

Results of Operations and F...

Compliance Regained

EQ101 Phase 2 Study Enrollm...

Financial Results and Study...

Equillium Investor Day

Open Market Sale Agreement

Earnings Reports

Termination of Loan Agreement

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

External Links:

Equillium, Inc. announced that Ono Pharmaceutical has allowed its option to acquire rights to itolizumab to lapse, and the company is pausing enrollment in its EQUATOR study while aiming to accelerate timelines for topline data to early 2025, maintaining cash runway into Q4 2025.

AI Assistant

EQUILLIUM INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.